Barbara Gayle Duncan, Chief Financial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 5,625 shares at $257.27 ($1.5M) on 2014-01-15, disclosed to the SEC on 2014-01-17.
Scheduled sale ($1.5M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $251.55 | 300 | $75K | 5.2% |
| 2 | $253.63 | 1,150 | $292K | 20.0% |
| 3 | $255.00 | 500 | $128K | 8.7% |
| 4 | $256.00 | 500 | $128K | 8.8% |
| 5 | $257.27 | 750 | $193K | 13.2% |
| 6 | $258.30 | 500 |
| $129K |
| 8.9% |
| 7 | $260.00 | 500 | $130K | 8.9% |
| 8 | $262.00 | 250 | $66K | 4.5% |
| 9 | $263.00 | 250 | $66K | 4.5% |
| 10 | $264.00 | 250 | $66K | 4.5% |
| 11 | $265.00 | 250 | $66K | 4.5% |
| 12 | $274.00 | 50 | $14K | 0.9% |
| 13 | $280.00 | 125 | $35K | 2.4% |
| 14 | $283.90 | 250 | $71K | 4.9% |
| Total | $259.19 avg | 5,625 | $1.5M | 100% |
| Filing → |
| JNCE | SELL | 2018-01-29 | $100K | — | Filing → |
| GNMX | BUY | 2017-10-18 | $150K | — | Filing → |
| ICPT | SELL | 2016-10-05 | $24K | — | Filing → |